EXAGEN INC. (XGN): Price and Financial Metrics


EXAGEN INC. (XGN)

Today's Latest Price: $11.65 USD

0.28 (2.46%)

Updated Jul 16 11:29am

Add XGN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

XGN Daily Price Range
XGN 52-Week Price Range

XGN Stock Price Chart Technical Analysis Charts


XGN Price/Volume Stats

Current price $11.65 52-week high $29.86
Prev. close $11.37 52-week low $10.29
Day low $11.30 Volume 671
Day high $11.65 Avg. volume 51,863
50-day MA $12.55 Dividend yield N/A
200-day MA $16.74 Market Cap 147.22M

EXAGEN INC. (XGN) Company Bio


Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand.


XGN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

XGN Latest Social Stream


Loading social stream, please wait...

View Full XGN Social Stream

Latest XGN News From Around the Web

Below are the latest news stories about Exagen Inc that investors may wish to consider to help them evaluate XGN as an investment opportunity.

Exagen (XGN) in Focus: Stock Moves 7.9% Higher

Exagen (XGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Yahoo | July 1, 2020

Exagen and the Ohio State Innovation Foundation Announce Exclusive License Agreement and Research Collaboration for a Novel, Rule-In, Blood Test to Support the Diagnosis of Fibromyalgia

SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients…

GlobeNewswire | June 17, 2020

Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus

Exagen Inc. (XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a clinical trial in collaboration with Duke University in Durham, NC. The Duke Lupus Clinic is focused on diagnosing, treating, and providing expert care to patients living with lupus. This prospective study will evaluate biomarkers, including the AVISE panel and Cell-Bound Complement Activation Products (CB-CAPs), that distinguish between changes in subsets of lupus patients with Type 1 and Type 2 systemic lupus erythematosus (SLE) activity.

Yahoo | June 3, 2020

Exagen to Present at the William Blair 40th Annual Growth Stock Conference

SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients…

GlobeNewswire | May 26, 2020

Exagen Inc. (XGN) Q1 2020 Earnings Call Transcript

Earlier today, Exagen Inc. released financial results for the quarter ended March 31, 2020. Ron Rocca, president and chief executive officer; and Kamal Adawi, chief financial officer, will host this afternoon's call.

Yahoo | May 14, 2020

Read More 'XGN' Stories Here

XGN Price Returns

1-mo -16.31%
3-mo -18.07%
6-mo -50.43%
1-year N/A
3-year N/A
5-year N/A
YTD -54.13%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7919 seconds.